GNPX
Genprex, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.06
−2.37%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.17
From 52W high−99.48%
Volume244671.00
Market cap$1.69M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.17
From 52W high
−99.48%
Volume
244671.00
Market cap
$1.69M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.9x
P/E (TTM)
—
RSI (14)
27.2
MomentumView details →
1D Return
−2.37%
YTD Return
−94.32%
SummaryUpdated Jun 1, 2026
Genprex, Inc. (NASDAQ:GNPX) is a clinical-stage biotechnology company founded in 2009 and headquartered in Austin, Texas. The company went public in March 2018 and focuses on developing innovative gene therapies for patients suffering from cancer and diabetes. As a clinical-stage company, Genprex does not yet generate meaningful revenue from product sales but instead relies on raising capital to fund its research and development activities as it advances its therapeutic candidates through various stages of clinical trials.
Similar companies
Latest newsMore news →
Genprex entered into a development and manufacturing agreement with a leading U.S.-based CDMO to scale up manufacturing of its diabetes gene therapy program, transitioning from research-grade to clinical and commercial-ready production.63d agoGenprex announced a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer clinical trials.78d ago